Enanta Pharmaceuticals
ENTA
100 hedge funds and large institutions have $287M invested in Enanta Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 33 increasing their positions, 44 reducing their positions, and 18 closing their positions.
106% more call options, than puts
Call options by funds: $140K | Put options by funds: $68K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.42% less ownership
Funds ownership: 105.91% → 104.49% (-1.4%)
7% less funds holding
Funds holding: 107 → 100 (-7)
25% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 44
27% less capital invested
Capital invested by funds: $391M → $287M (-$104M)
39% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 18
Top Buyers
| 1 |
Citadel Advisors
Miami,
Florida
|
+$5.53M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$2.96M |
| 3 |
CP
Caligan Partners
New York
|
+$2.49M |
| 4 |
KAM
Krensavage Asset Management
New York
|
+$1.71M |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$1.28M |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$7.95M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$2.12M |
| 3 |
AC
Armistice Capital
New York
|
-$1.89M |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$1.19M |
| 5 |
Two Sigma Investments
New York
|
-$982K |
ENTA Hedge Fund Activity: Q2 2024 in Review
100 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q2 2024, worth a combined $287M — down 27% from $391M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of ENTA and 11 opened new positions — a net loss of 7 holders — while 44 trimmed existing stakes and 33 added.
The largest buyer was Citadel Advisors, adding an estimated $5.53M. The largest seller was Morgan Stanley, cutting an estimated $7.95M.
- 100 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q2 2024, down from 107 in Q1 2024.
- Funds reported $287M of Enanta Pharmaceuticals stock for Q2 2024, down 27% quarter-over-quarter.
- 11 funds opened new Enanta Pharmaceuticals positions in Q2 2024 and 18 closed out, a net change of -7 holders.
- The largest Enanta Pharmaceuticals buyer in Q2 2024 was Citadel Advisors, an estimated $5.53M added.
- The largest Enanta Pharmaceuticals seller in Q2 2024 was Morgan Stanley, an estimated $7.95M sold.
Based on aggregated 13F filings for Q2 2024.